Navigation Links
Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
Date:6/17/2008

CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study will involve up to fifty-three subjects with SP-MS who will receive the drug once weekly in four escalating-dose cohorts. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in multiple sclerosis patients in early 2009.

"While the primary goal of this study is to demonstrate safety of PI-2301 in multiple sclerosis patients, we believe that this clinical trial is one of the most comprehensive looks at the pharmacologic effects of any immunomodulator in patients suffering from autoimmune diseases," stated Thomas P. Mathers, President and CEO of Peptimmune. Mr. Mathers will be presenting an overview of the PI-2301 clinical program at the BIO 2008 Business Forum, Wednesday, June 18th, at 9:00 a.m. PDT at the San Diego Convention Center, Room 2.

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechan
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
4. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
5. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
6. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
7. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...cal Incorporated (Nasdaq: VICL ) announced today...rom Merck & Co., Inc. based on Merck,s planned...stigational plasmid DNA (pDNA) cancer vaccine. The...livery technology and encodes human telomerase rev...f separate license agreement. , , "The brea...
(Date:11/28/2008)...- Eli Lilly and Company,(NYSE: LLY ) has withdr...rom,the U.S. Food and Drug Administration (FDA) f...t of chronic pain. Lilly plans to resubmit the app...rom a recently completed positive study,in chroni...cision does not affect duloxetine,s FDA-approved i...
(Date:11/26/2008)...KLIN, Mass., Nov. 26 PLC...d today that it has received full approval from th...U.S. pivotal trial to study the effectiveness of t... therapy in the prevention of Contrast-Induced Nep...LC,s request to expand their investigation from th...
(Date:11/25/2008)...re/ -- Proteolix, Inc., a,leader in the discovery...,protein degradation pathways in cancer and autoi...o ongoing Phase 2 clinical trials of carfilzomib i...ing 50th Annual Meeting of the,American Society o... new class,of specific proteasome inhibitors and ...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3LI COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging 8527 1LI COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging 8527 2DFG continues to strengthen biodiversity research 5543 1DFG continues to strengthen biodiversity research 5543 2Innovative strategies for war wounded 5538 1Innovative strategies for war wounded 5538 2Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 1Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 2Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 3
...lso Support Drug,s Efficacy at Improving Glycemic ...ications, CHICAGO, Ill., June 23, 2007 /PRNewswire...mercialization partner S2 Therapeutics,Inc., repo...trial,supporting the overall and cardiovascular sa...of bromocriptine mesylate) in subjects,with type 2...
...R CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--Gi...that Study 103, a,Phase III clinical trial evaluat...R) (tenofovir disoproxil fumarate or tenofovir,DF)...itis B virus,(HBV) infection, met its primary effi...ferior to the company,s once-daily antiviral,drug ...
Other Medicine Technology:Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
(Date:12/1/2008)... Dec. 1 Actavis Group, the interna...unced that it has received approval from the U.S. ... Hydrochloride extended-release tablets (XL) 150mg... , Bupropion Hydrochloride extended-release ...h, are the generic equivalent of Wellbutrin XL(R) ...
(Date:12/1/2008)... , Ideas from U-M physician include economical... A bottle of cologne, a... and easy gifts to buy and wrap for the upcoming h...ng more healthy and beneficial to a loved one? Why...healthy around the holidays can be challenging, an...
(Date:12/1/2008)...PRNewswire/ -- Resurrection Health Care has been r...lthcare by Modern Healthcare,magazine. The nation...ing,homes, retirement communities, home health se...ices throughout the Chicago area. , Modern ...s health care,organizations nationwide that enabl...
(Date:12/1/2008)... 1 Prior generations often shared,...ents -- typically because,seniors didn,t live far...h,life expectancy having increased by an average ...mbered by health care concerns, which may make old...emselves. In the recently published,Evercare(R) S...
Breaking Medicine News(10 mins):Health News:Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S. 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:Resurrection Health Care Named One of Nation's 'Best Places to Work in Healthcare' 2Health News:Take Time to Care for the Caregiver 2
... the brain of youngsters, says a study, which stre... can do to them. // Thomas Heffernan, a psychologi...llege students for the research presented at the B...s annual conference in York, reported the online e...
...r still remains the best way to ensure patient s...ring the 85th General Session of the International...the University of California-Irvine presented two ...approaches to oral cancer detection, diagnostic sc...
...m Aberdeen University are on the brink of another ...s of lives,// by an early diagnosis of cancer, Alz...ther disorders. A prototype of an MRI scanner has...ferent images, compared to one image from current ...
...oon urged governments to join the anti-tuberculosi...n coming years as// the disease has become extreme...ng the importance of World TB Day on Saturday. The...tly reported about the rise in the extensively dru...
Other Medicine News:Health News:Novel Methods in Diagnosing Oral Cancer 2Health News:Breakthrough in MRI Scanning in the Near Future 2
15" overall length, 9" handle.
Gimmi Yasargil Aneurysm-Vessel-Clips
Yasargil Phynox Aneurysm Clips Standard
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in
Medicine Products: